Vasundhara Rasayans Ltd
Incorporated in 1987, Vasundhara Rasayans Ltd is a manufacturer and exporter of Antacids[1]
- Market Cap ₹ 48.9 Cr.
- Current Price ₹ 154
- High / Low ₹ 220 / 100
- Stock P/E 8.28
- Book Value ₹ 129
- Dividend Yield 1.30 %
- ROCE 20.2 %
- ROE 15.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.20 times its book value
Cons
- The company has delivered a poor sales growth of 9.51% over past five years.
- Earnings include an other income of Rs.2.59 Cr.
- Debtor days have increased from 60.7 to 76.2 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.40 | 15.27 | 15.41 | 16.58 | 19.71 | 21.17 | 22.68 | 26.70 | 37.88 | 36.96 | 33.99 | 35.72 | 35.09 | |
| 16.80 | 13.97 | 13.76 | 14.78 | 18.55 | 18.33 | 19.57 | 24.49 | 32.32 | 30.53 | 29.88 | 29.88 | 28.93 | |
| Operating Profit | 1.60 | 1.30 | 1.65 | 1.80 | 1.16 | 2.84 | 3.11 | 2.21 | 5.56 | 6.43 | 4.11 | 5.84 | 6.16 |
| OPM % | 8.70% | 8.51% | 10.71% | 10.86% | 5.89% | 13.42% | 13.71% | 8.28% | 14.68% | 17.40% | 12.09% | 16.35% | 17.55% |
| 0.31 | 0.25 | 0.44 | 7.74 | 1.04 | 1.15 | 0.99 | 1.04 | 2.30 | 1.94 | 2.35 | 2.90 | 2.59 | |
| Interest | 0.53 | 0.57 | 0.39 | 0.17 | 0.08 | 0.06 | 0.09 | 0.09 | 0.25 | 0.21 | 0.34 | 0.45 | 0.32 |
| Depreciation | 0.50 | 0.56 | 0.56 | 0.32 | 0.05 | 0.03 | 0.05 | 0.12 | 0.13 | 0.26 | 0.36 | 0.43 | 0.46 |
| Profit before tax | 0.88 | 0.42 | 1.14 | 9.05 | 2.07 | 3.90 | 3.96 | 3.04 | 7.48 | 7.90 | 5.76 | 7.86 | 7.97 |
| Tax % | 34.09% | 45.24% | 59.65% | 28.07% | 29.95% | 23.59% | 25.76% | 28.62% | 25.27% | 25.82% | 26.39% | 26.46% | |
| 0.58 | 0.24 | 0.46 | 6.52 | 1.45 | 2.99 | 2.94 | 2.17 | 5.59 | 5.86 | 4.25 | 5.79 | 5.91 | |
| EPS in Rs | 1.82 | 0.76 | 1.45 | 20.51 | 4.56 | 9.41 | 9.25 | 6.83 | 17.59 | 18.44 | 13.37 | 18.22 | 18.60 |
| Dividend Payout % | 27.41% | 0.00% | 69.13% | 4.88% | 21.93% | 15.95% | 16.22% | 14.65% | 0.00% | 0.00% | 14.96% | 10.98% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | -2% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 37% |
| 5 Years: | 15% |
| 3 Years: | 1% |
| TTM: | 50% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 4% |
| 3 Years: | -12% |
| 1 Year: | -20% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 16% |
| 3 Years: | 16% |
| Last Year: | 15% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 |
| Reserves | 3.72 | 3.96 | 4.04 | 10.56 | 11.63 | 14.23 | 16.69 | 18.36 | 23.64 | 28.76 | 32.38 | 37.70 |
| 5.58 | 5.01 | 3.10 | 1.41 | 0.46 | 0.00 | 0.00 | 1.31 | 4.02 | 1.95 | 4.21 | 1.81 | |
| 4.16 | 3.21 | 3.13 | 5.23 | 5.56 | 7.28 | 3.14 | 2.66 | 3.68 | 3.41 | 3.30 | 5.19 | |
| Total Liabilities | 16.64 | 15.36 | 13.45 | 20.38 | 20.83 | 24.69 | 23.01 | 25.51 | 34.52 | 37.30 | 43.07 | 47.88 |
| 7.62 | 7.28 | 6.78 | 0.10 | 0.20 | 0.30 | 0.67 | 0.91 | 0.86 | 2.43 | 2.49 | 2.35 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.23 | 0.18 | 0.07 | 1.10 | 1.23 | 0.97 | 1.12 | 0.32 | 0.00 | 1.16 | 2.35 | 2.51 |
| 8.79 | 7.90 | 6.60 | 19.18 | 19.40 | 23.42 | 21.22 | 24.28 | 33.66 | 33.71 | 38.23 | 43.02 | |
| Total Assets | 16.64 | 15.36 | 13.45 | 20.38 | 20.83 | 24.69 | 23.01 | 25.51 | 34.52 | 37.30 | 43.07 | 47.88 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.56 | 1.32 | 2.42 | -10.70 | 0.43 | 0.36 | 0.22 | 7.90 | -6.50 | 6.03 | -5.83 | -1.58 | |
| -2.02 | -0.06 | 0.07 | 13.30 | 0.53 | 1.02 | 0.16 | 1.39 | 1.27 | -1.32 | 0.46 | 2.01 | |
| 0.46 | -1.28 | -2.24 | -2.26 | -1.36 | -0.87 | -0.49 | 0.79 | 2.19 | -2.88 | 1.35 | -3.44 | |
| Net Cash Flow | 0.00 | -0.01 | 0.24 | 0.33 | -0.41 | 0.50 | -0.12 | 10.08 | -3.04 | 1.83 | -4.02 | -3.01 |
| Free Cash Flow | -0.50 | 1.10 | 2.38 | 3.34 | 0.29 | 0.23 | -0.20 | 7.55 | -6.58 | 4.20 | -6.25 | -1.88 |
| CFO/OP | 117% | 114% | 164% | -457% | 153% | 36% | 51% | 397% | -95% | 125% | -78% | -13% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74.39 | 93.22 | 89.53 | 131.65 | 94.63 | 107.41 | 99.30 | 100.34 | 77.57 | 61.43 | 44.56 | 76.23 |
| Inventory Days | 45.71 | 53.90 | 69.11 | 64.32 | 60.51 | 59.00 | 48.01 | 57.91 | 79.48 | 38.86 | 44.33 | 36.74 |
| Days Payable | 59.78 | 31.68 | 52.91 | 62.28 | 45.28 | 59.39 | 76.61 | 57.65 | 48.68 | 40.43 | 42.91 | 67.68 |
| Cash Conversion Cycle | 60.32 | 115.44 | 105.73 | 133.69 | 109.85 | 107.02 | 70.70 | 100.60 | 108.36 | 59.85 | 45.98 | 45.29 |
| Working Capital Days | 11.90 | 12.43 | 14.69 | 258.67 | 245.56 | 267.41 | 143.88 | 127.82 | 174.50 | 193.76 | 274.47 | 344.26 |
| ROCE % | 12.04% | 8.04% | 13.44% | 14.21% | 14.14% | 23.75% | 21.73% | 12.92% | 28.79% | 25.06% | 16.56% | 20.16% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Domestic revenue INR Lakhs |
|
|||||
| Export revenue INR Lakhs |
||||||
| Number of permanent employees employees |
||||||
| Customer concentration - top 3 customers as % of trade receivables % |
||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper publication of unaudited financial results for the quarter ended on 30.06.2026
-
Financial Results For The Quarter Ended 30.06.2026
- Board approved Q1 FY2026 unaudited results; net profit rose to Rs64.80 lakh, with unmodified review report.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14.08.2026
- Q1 FY27 unaudited results approved; net profit Rs 64.80 lakh, sales Rs 693.23 lakh.
-
Board Meeting Intimation for FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30.06.2026
- Board meeting on 14 August 2026 to approve Q1 FY2026-27 unaudited financial results.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Intimation regarding Newspaper Advertisement for publication of notice of Annual General Meeting
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1][2]
VRL manufactures and exports Antacids
therapeutic category of Active Pharma Ingredients and offers products in paste, powder and micronized grade of powder. Additionally, it offers products which are used other than pharmaceutical use.